{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:42:48Z","timestamp":1791744168453,"version":"4.3.4"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jcpo.2021.100303","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T11:49:11Z","timestamp":1630583351000},"page":"100303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Experiences and perspectives of individuals accessing CAR-T cell therapy: A qualitative analysis of online Reddit discussions"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3635-5212","authenticated-orcid":false,"given":"Kristina","family":"Jenei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2193-3785","authenticated-orcid":false,"given":"Adam J.N.","family":"Raymakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2021.100303_bib0005","unstructured":"FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma | FDA. [Online]. Available: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-large-b-cell-lymphoma. [Accessed: 13-May-2021]."},{"issue":"December (22)","key":"10.1016\/j.jcpo.2021.100303_bib0010","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1001\/jama.2017.15605","article-title":"The promise and challenges of CAR-T gene therapy","volume":"318","author":"Kuehn","year":"2017","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"10.1016\/j.jcpo.2021.100303_bib0015","series-title":"Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications","first-page":"1","author":"Whittington","year":"2019"},{"issue":"November (32)","key":"10.1016\/j.jcpo.2021.100303_bib0020","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia","volume":"36","author":"Lin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jcpo.2021.100303_bib0025","first-page":"1","article-title":"\u2018r\/Thritis\u2019, pregnancy, and parenting: a qualitative descriptive study of Reddit forums to explore information needs and concerns of women with rheumatoid arthritis","author":"Chew","year":"2019","journal-title":"ACR Open Rheumatol."},{"issue":"8","key":"10.1016\/j.jcpo.2021.100303_bib0030","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G","article-title":"Whatever happened to qualitative description?","volume":"23","author":"Sandelowski","year":"2000","journal-title":"Res. Nurs. Health"},{"issue":"3","key":"10.1016\/j.jcpo.2021.100303_bib0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.healthpol.2009.01.005","article-title":"Public participation in health care priority setting: a scoping review","volume":"91","author":"Mitton","year":"2009","journal-title":"Health Policy (New. York)"},{"key":"10.1016\/j.jcpo.2021.100303_bib0040","first-page":"1362","article-title":"Tracking health related discussions on Reddit for public health applications","volume":"vol. 2017","author":"Park","year":"2017"},{"issue":"May (21)","key":"10.1016\/j.jcpo.2021.100303_bib0045","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1056\/NEJMp0900702","article-title":"Digital disease detection \u2014 harnessing the web for public health surveillance","volume":"360","author":"Brownstein","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jcpo.2021.100303_bib0050","article-title":"The impact and influence of hope and hype in decision-making about health technologies","volume":"28","author":"Simpson","year":"2015","journal-title":"Healthc. Manag."},{"issue":"January (1)","key":"10.1016\/j.jcpo.2021.100303_bib0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamaoncol.2015.3931","article-title":"The use of superlatives in cancer research","volume":"2","author":"Abola","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jcpo.2021.100303_bib0060","unstructured":"The Cancer Industry: Hype vs. Reality - Scientific American Blog Network. [Online]. Available: https:\/\/blogs.scientificamerican.com\/cross-check\/the-cancer-industry-hype-vs-reality\/. [Accessed: 14-May-2021]."},{"key":"10.1016\/j.jcpo.2021.100303_bib0065","series-title":"Medical Crowdfunding to Access CAR T-Cell Therapy","author":"Ho","year":"2019"},{"key":"10.1016\/j.jcpo.2021.100303_bib0070","series-title":"A Resource Guide for Research Teams and Networks","article-title":"Patient engagement and Canada\u2019s SPOR initiative","author":"Abelson","year":"2015"}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538321000345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538321000345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:06:50Z","timestamp":1761988010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538321000345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":14,"alternative-id":["S2213538321000345"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2021.100303","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experiences and perspectives of individuals accessing CAR-T cell therapy: A qualitative analysis of online Reddit discussions","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2021.100303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100303"}}